BACKGROUND Major advances in our understanding of the underlying biology of prostate
cancer have helped to herald a new era in the treatment of castration-resistant prostate …

Castration-resistant prostate cancer (CRPC) is associated with a poor prognosis and poses
considerable therapeutic challenges. Recent genetic and technological advances have …

Advances in genomic sequencing and molecular characterization are improving our
understanding of the biology of prostate cancer and challenging us to translate emerging …

Abstract Treatment options for patients with advanced prostate cancer (PCa) remain limited.
Improved understanding of the underlying molecular drivers of PCa pathogenesis …

In 2007, drug development in castration-resistant metastatic prostate cancer (CRPC)
remains challenging, due to the number of potentially viable molecular targets and clinical …

Prostate cancer is the most common cause of cancer in men, with 137.9 new cases per
100,000 men per year. The overall 5-year survival rate for prostate cancer is very high. Up to …

Men who develop metastatic castration-resistant prostate cancer (mCRPC) will invariably
succumb to their disease. Thus there remains a pressing need for preclinical testing of new …

KEY POINTS The Prostate Cancer Working Group (PCWG2) was convened to define
consensus criteria for eligibility and outcome measures in trials evaluating systemic …

Recurrent prostate cancer has a complex molecular etiology and a prolonged disease
course. Although initially responsive to androgen ablation, many men eventually become …

Introduction: The armamentarium of treatment options in metastatic and non-metastatic
CRPC is rapidly evolving. However, the question of how individual treatment decisions …